Acura Pharmaceuticals

Acura Pharmaceuticals is a U.S.-based public company developing and licensing abuse-deterrent drug delivery technologies. Its core business revolves around three proprietary platforms: LIMITX™ for limiting release upon oral overdose, AVERSION® for deterring snorting and injection of opioids, and IMPEDE® for hindering the extraction of pseudoephedrine for methamphetamine production. The company has transitioned to a licensing model, with its lead LIMITX™ candidate (LTX-03) partnered with Abuse Deterrent Pharmaceuticals, while its AVERSION® and IMPEDE® technologies are already commercialized through partnerships with Zyla Life Sciences (OXAYDO®) and MainPointe Pharmaceuticals (Nexafed®), respectively. Acura's strategy targets the significant public health need and regulatory push for safer pain and cold medications.

Three proprietary drug delivery platforms: LIMITX™ (limits drug release on oral overdose), AVERSION® (deters snorting/injection via gelling/irritants), and IMPEDE® (hinders pseudoephedrine extraction for meth production).

Acura competes in the abuse-deterrent formulation space with larger pharmaceutical companies (e.g., Purdue Pharma's OxyContin, Collegium's Xtampza ER) and other specialty firms. Its focus on immediate-release opioids (OXAYDO) and novel overdose protection (LIMITX) differentiates it, but it faces commercial scale and marketing challenges compared to big pharma.